BIO.News Newsletter

Madonna was hospitalized with a “serious bacterial infection”—the kind of headline we could see more frequently if we don’t develop new antimicrobials. Here’s what we know, plus a look at a recent report on the life sciences workforce and job market. (507 words, 2 minutes, 32 seconds)

Cases of locally acquired malaria have been detected in the U.S.—for the first time in 20 years. Here’s what’s happening. Plus, a new episode of the Vital Transformation podcast features BIO’s Nick Shipley explaining why the IRA is challenging the innovation ecosystem. (540 words, 2 minutes, 39 seconds)

Beech leaf disease is ravaging East Coast beech trees—we explain what’s happening and why biotech offers a glimmer of hope. Plus, a look at how we can grow the biotech workforce with education initiatives. (518 words, 2 minutes, 35 seconds)

Experts presenting at Friday’s CDC ACIP meeting confirmed that the childhood vaccination schedule is safe—and benefits outweigh known and possible risks. Plus, it’s hard to ignore the fact that air quality is getting worse—we explore why it matters to health and how biotech can help. (533 words, 2 minutes, 39 seconds)

Ending the week with a win—actually three, as Congress introduced three important bills drafted with BIO support. And as National Pollinator Week comes to a close, we explore how biotech is giving a boost to bees. (678 words, 3 minutes, 23 seconds)

A busy news day: USDA approves cultivated meat, House members talk PBM transparency, and CDC advisers recommend RSV shots for people over 60, among other headlines. (694 words, 3 minutes, 28 seconds)

Today, a look at a new working group to drive harmonization of cell and gene therapies worldwide (which BIO supports) and what one member of Congress said about the Inflation Reduction Act and orphan drugs. (682 words, 3 minutes, 24 seconds)

The Paris Air Show puts a spotlight on SAF, and World Sickle Cell Day (yesterday) highlights the importance of advancing new treatments—which could be here soon. (571 words, 2 minutes, 51 seconds)

The House Ways & Means Committee takes a welcome first step on R&D amortization—plus, we explore how the biopharma industry is reducing emissions and improving sustainable practices. (521 words, 2 minutes, 36 seconds)

A hearing yesterday explained how price controls will impact rare disease R&D—plus, we need to be scared about AMR. (594 words, 2 minutes, 58 seconds)